Searchable abstracts of presentations at key conferences in endocrinology

ea0063p256 | Pituitary and Neuroendocrinology 1 | ECE2019

Hyperglycemia and pasireotide lar in acromegaly: a study with continuous glucose monitoring

Russo Lucia , Mazzocut Sara , Dassie Francesca , Parolin Matteo , Martini Chiara , Carlo Eugenio De , Fallo Francesco , Mioni Roberto , Vettor Roberto , Maran Alberto , Maffei Pietro

Background: Pasireotide LAR is a multireceptor targeted somatostatin analogue that has been shown to obtain a better biochemical control of acromegaly. However, pasireotide LAR could induce hyperglycemia in acromegalic patients with higher baseline glucose values. The devices that can track interstitial glucose levels such as continuous glucose monitoring (CGM) could be a useful for studying the impact of SSA on patients’ glucose status.Aim: We aime...

ea0081ep1201 | Late Breaking | ECE2022

Impact of COVID-19 outbreak on acromegaly patients management

Filippi Elisa , Camerini Silvia , Spinello Marica , Vettor Roberto , Maffei Pietro , Dassie Francesca

Introduction: Acromegaly is a chronic disease that requires continuous follow-up and examinations over time. During the COVID-19 pandemic outbreak many endocrinological scientific societies recommend to reduce pituitary patient access to hospital facilities to decrease risk of infection. Aim: The aim of our study is to evaluate the impact of restrictions on outpatient access in the clinical management of the patient with acromegaly during COVID19 pandemi...

ea0063p597 | Diabetes, Obesity and Metabolism 2 | ECE2019

A new neurocognitive phenotype in Alstrom sindrome

Lorusso Riccardina , Dassie Francesca , Benavides-Varela Silvia , Milan Gabriella , Favaretto Francesca , Vettor Roberto , Semenza Carlo , Maffei Pietro

Background: Alstrom syndrome (AS; OMIM#203800) is a rare (<1:100.000) autosomal recessive monogenic ciliopathy and it is caused by mutations in ALMS1 (chromosome 2p13), which function is still unknown. AS is characterized by multisystemic fibrosis, cone-rod retinal dystrophy leading to blindness, hearing loss, obesity, type 2 diabetes mellitus (T2DM), dilated cardiomyopathy, and progressive hepatic and renal failure. Most patients present neurological issue on developmenta...

ea0048p1 | Poster Presentations | SFEEU2017

Weight loss and associated improvements in cardiometabolic risk factors with liraglutide 3.0 mg in the SCALE Obesity and Prediabetes randomised, double-blind, placebo-controlled 3-year trial

McGowan Barbara , Fujioka Ken , Greenway Frank , Krempf Michel , Le Roux Carel , Vettor Roberto , Lilleore Soren , Astrup Arne

Aims/objectives: Obesity and prediabetes are risk factors for developing T2D. 5–10% weight-loss can reduce risk of developing T2D by >50%. The 3-year part of this phase 3 trial investigated effects of liraglutide 3.0 mg, as adjunct to diet+exercise, in delaying onset of T2D over 3 years, body-weight and cardiometabolic risk factors in adults with obesity or overweight with comorbidities, and diagnosed with prediabetes at screening.Methods: Indiv...

ea0070aep1066 | Hot topics (including COVID-19) | ECE2020

Effect of long term rhgh treatment on bone mineral density in patients with childhood onset growth hormone deficiency

Dassie Francesca , Spinazze Alice , Russo Lucia , Parolin Matteo , Mioni Roberto , Maffei Pietro , Zaccaria Marco , Vettor Roberto , De Carlo Eugenio

Background: RhGH treatment in adults with childhood onset growth hormone deficiency (COGHD) affect bone metabolism over time according to gender and age. A long-term study of bone mass density (BMD) in young-middle age hypopituitary patients with COGHD may better highlight possible benefits of therapy and improve clinical follow up.Methods: We enrolled 40 adults (age range during follow-up: 16.8–36 years, F: 38%) with COGHD with at least 20 years o...

ea0090p339 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

Therapy of overweight and obesity resistant to behavioral treatment in the adult population with metabolic comorbidities. A network meta-analysis

Samperi Irene , Persichetti Agnese , Attanasio Roberto , Busetto Luca , Cinquini Michela , Paoletta Agostino , Papini Enrico , Novizio Roberto , Scoppola Alessandro , Vettor Roberto , Chianelli Marco

Background: Overweight and obesity are an increasing concern for public health worldwide. Obesity is a chronic, progressive and relapsing disease associated with the development of several comorbidities which may improve after weight loss. The first step in the management of weight excess includes life-style modifications but, in the long-term, obesity is frequently resistant to life-style changes only. Surgical procedures and medical treatments have, therefore, been developed...

ea0063gp50 | Acromegaly and GH | ECE2019

Sleep disorders and cognitive dysfunction in acromegaly

Dassie Francesca , Wennberg Alexandra , Lorusso Riccardina , Parolin Matteo , Russo Lucia , Mazzocut Sara , Benavides-Varela Silvia , De Carlo Eugenio , Martini Chiara , Vettor Roberto , Semenza Carlo , Maffei Pietro

Background: In the general population, sleep disorders are associated with an increased risk of cognitive impairment; moreover, people with dementia often have sleep disturbances. The prevalence of sleep disorders, such as sleep apnea, in acromegalic patients is higher than in the general population, and they may have a higher risk of cognitive impairment due to acromegaly treatment (i.e. Radiotherapy) or cardiovascular comorbidities. In the literature, data about the relation...

ea0063p736 | Pituitary and Neuroendocrinology 2 | ECE2019

Prevalence of silent acromegaly in prolactinomas (PASP): an Italian experience

Bona Chiara , Prencipe Nunzia , Mantonavi Giovanna , Lanzi Roberto , Jaffrain-Rea Marie-Lise , Ambrosio Maria Rosaria , Pasquali Daniela , Vettor Roberto , Cannavo Salvatore , Ghigo Ezio , Grottoli Silvia

Patients with prolactinomas may develop acromegaly during D2-agonists (DA), suggesting the existence of somatomammotroph adenomas with asynchronous secretion of GH and PRL. This may be due to the acquisition of somatotroph characteristics by lactotroph cells or to GH co-secretion by somatommammotroph cells unmasked after PRL inhibition by DA. The prevalence of silent acromegaly in prolactinomas during DA is 4.1%. The purpose of this study was to evaluate the somatotroph axis i...

ea0063p1101 | Pituitary and Neuroendocrinology 3 | ECE2019

Pegvisomant: daily versus non daily administration a single centre real life study

Dassie Francesca , Rosson Marco , Parolin Matteo , Russo Lucia , Mazzocut Sara , Martini Chiara , De Carlo Eugenio , Mioni Roberto , Fallo Francesco , Vettor Roberto , Maffei Pietro

Background: Pegvisomant (PEG) is a second line medical treatment for active acromegalic patients. PEG efficacy is between 61.5 and 92% and even if it is administered daily its long half-life suggests a possible use with a non-daily regime.Aim: We aim to compare acromegalic patients on daily PEG administration (DP) with patients on non-daily PEG administration (NDP).Methods: We studied 43 acromegalic patients under PEG treatment bet...